Anhydro Ara C, also known as Arabinofuranosyl Cytosine or N4-Acetylderiv of Anhydrodeoxy Arabinohydroxymethyl Cytosine, is a nucleoside analog drug used in the treatment of various types of cancers. It belongs to the group of chemotherapeutic agents called antimetabolites.
Anhydro Ara C is derived from the naturally occurring nucleoside cytosine and is chemically modified to enhance its effectiveness as an anticancer drug. It works by inhibiting the synthesis of DNA molecules, resulting in the disruption of cancer cell growth and division.
The drug is primarily used to treat leukemias, particularly acute myeloid leukemia (AML). It can also be used in combination with other chemotherapy drugs or radiation therapy to increase treatment efficacy. Anhydro Ara C is administered through intravenous infusion or injection and is typically given in cycles, allowing the patient's body to recover between treatments.
Like other chemotherapy drugs, Anhydro Ara C can cause various side effects such as bone marrow suppression, nausea, vomiting, hair loss, and mouth sores. Regular monitoring of blood counts and liver function is necessary during treatment to ensure patient safety and adjust the dosage if needed.
Overall, Anhydro Ara C is a potent antimetabolite drug that works by interfering with cancer cell DNA synthesis. It is an essential component of cancer treatment regimens and has shown significant efficacy in improving patient outcomes in certain types of cancers, especially AML.
